Richard Chu, DO
Ophthalmology · Fort Worth, TXNPI 1164728044
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Sight Sciences, Inc. at 47.9% of the total. 2025 is the largest year on record at $19,589, more than ten times the $850 reported in 2019. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $143.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$22K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$10K
- Glaukos Corporation$3K
- Alcon$3K
- Johnson & Johnson Surgical Vision, Inc.$3K
- Biotissue Holdings Inc.$2K
- plus $3K from 23 others
Across 204 payments — averaging $813.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$166K
What the payments were for
- Consulting fees$8,47519%
- Speaking & faculty fees$24,60054%
- Travel & lodging$1,7604%
- Food & beverage$10,42923%
- Education$800%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 69 | $21,747 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 32 | $10,150 |
| Glaukos Corporation | 19 | $3,336 |
| Alcon | 72 | $2,837 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $2,597 |
| Biotissue Holdings Inc. | 25 | $1,693 |
| Bausch & Lomb Americas Inc. | 17 | $650 |
| AbbVie(2 entities) | 21 | $580 |
| Tarsus Pharmaceuticals, Inc. | 7 | $361 |
| Ocular Therapeutix, Inc. | 12 | $272 |
| Alcon Research LLC | 2 | $204 |
| Harrow Eye, LLC | 2 | $179 |
| Dompe US, Inc. | 5 | $125 |
| Novartis | 5 | $106 |
| Carl Zeiss Meditec USA, Inc. | 1 | $99 |
| Rayner Intraocular Lenses Limited | 4 | $90 |
| Eyepoint US, Inc. | 2 | $46 |
| Kala Pharmaceuticals, Inc. | 2 | $40 |
| Eyevance Pharmaceuticals LLC | 2 | $39 |
| CSL Behring | 2 | $37 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Amgen | 1 | $27 |
| Rxsight Inc | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| NEW World Medical,inc. | 1 | $18 |
| Thea Pharma Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Lensar, Inc. | 1 | $16 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$17,101
- SION SURGICAL INSTRUMENT$14,302
- LOTEMAX SM$9,760
- TearCare SmartLid$3,625
- TEARCARE(TM) (2.2) SYSTEM KIT$3,625
- iStent$2,500
- iStent inject W$2,500
- INTRALASE FS FEMTOSEC LASER$2,475
- Prokera$1,059
- AmnioGraft$1,059
- Precision 1$290
- MIEBO$243
- XDEMVY$232
- AcrySof IQ PanOptix$144
- KXL1B-CE-marked KXLsystem$144
- KXL System$144
- DAILIES TOTAL1$140
- XIIDRA$123
- PROLENSA$114
- iDoseTR$106
How this compares
$45,363 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 22 | $16,900 |
| Prednisolone Acetate | 292 | $15,068 |
| RestasisCyclosporine | 15 | $13,754 |
| XiidraLifitegrast | 12 | $11,493 |
| BesivanceBesifloxacin Hcl | 37 | $8,392 |
| LumiganBimatoprost | 14 | $8,376 |
| MoxifloxacinMoxifloxacin Hcl | 274 | $7,684 |
| Lotemax SmLoteprednol Etabonate | 27 | $6,812 |
| VyzultaLatanoprostene Bunod | 21 | $6,679 |
| Ketorolac Tromethamine | 211 | $5,389 |
| TobradexTobramycin/Dexamethasone | 20 | $5,325 |
| ProlensaBromfenac Sodium | 14 | $4,843 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 39 | $4,771 |
| Cyclosporine | 19 | $3,959 |
| Brimonidine Tartrate | 34 | $3,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $650 | $35,07255 claims |
| AbbVieRestasis, Lumigan | $580 | $22,13029 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Lotemax Sm, Prolensa | $10,150 | $20,04878 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Fort Worth
- Taylor StrangeFort Worth$179K
- Brett MuellerFort Worth$160K
- Brian FlowersFort Worth$156K
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.